Cancer Biomarkers Market Size To Reach $69.76 Billion By 2030

Cancer Biomarkers Market Growth & Trends

The global cancer biomarkers market size is expected to reach a value of USD 69.76 billion by 2030 and is anticipated to expand at a CAGR of 12.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. Growing initiatives for development of drugs targeting novel cancer biomarkers coupled with the introduction of technologically advanced companion diagnostic kits is estimated to provide the market with high growth potential. Increasing awareness about personalized medicines amongst patients is further anticipated to boost adoption of cancer biomarkers.

In addition, presence of favorable government initiatives for the development of novel cancer diagnostic techniques is a key factor for market growth. For instance, the National Cancer Institute (NCI) provides funding to more than 8 research areas pertaining to cancer biomarker development. Cancer Research UK, Lung Cancer Research Foundation, and National Institutes of Health are some of the organizations providing funding for biomarker research.

People with high alcohol consumption, tobacco usage, unhealthy food habits, and sedentary lifestyle are reported to be 80% more at risk of developing cancer as compared to other individuals. Infections such as Human papillomavirus (HPV), Epstein-Barr virus, Hepatitis B virus, and Helicobacter pylori are also been studied to be related in cancer development.

 Request a free sample copy or view report summary: Cancer Biomarkers Market Report

Cancer Biomarkers Market Report Highlights

• The breast cancer segment held a significant market share in terms of revenue in 2023 and it is also expected to be the witness the fastest CAGR over the forecast period.

• The others segment held a notable share in 2023 pertaining to the increased research on rare cancers, advancements in genomics and proteomics, the rising incidence of cancers such as pancreatic and ovarian, and the growing demand for personalized medicine.

• The genetic biomarkers segment dominated the market in terms of revenue share in 2023. Genetic biomarkers are crucial in the cancer biomarkers market due to several driving factors.

• The epigenetics segment is expected to be the fastest growing segment over the forecast period. One of the key drivers boosting the growth of the segment is the growing research for the development of novel biomarkers.

• The diagnostics segment dominated the market in terms of revenue share in 2023. Factors such as the growing development of cancer biomarkers based on oncology tests that are highly efficient and effective and growing government initiatives may drive the segment's growth.

• The personalized medicine segment is the fastest growing segment during the forecast period.

• The imaging technologies segment dominated the market share in 2023 due to its high-throughput nature, accuracy, and broad applicability in biomarker discovery and diagnosis.

• North America dominated the cancer biomarkers market with revenue share of 43.84% in 2023. This dominance is due to the presence of numerous market players dedicated to cancer biomarkers and substantial investments by the U.S. government in research and development efforts, which foster innovation.

• Asia Pacific cancer biomarkers market is anticipated to witness the fastest growth at a CAGR of 14.3% over the forecast period.

Cancer Biomarkers Market Segmentation

Grand View Research has segmented global cancer biomarkers market report based on type, biomolecule, application, technology, and region:

Cancer Biomarkers Type Outlook (Revenue, USD Million; 2018 - 2030)

• Breast cancer

• Prostate cancer

• Colorectal cancer

• Cervical cancer

• Liver cancer

• Lung cancer

• Others

Cancer Biomarkers Biomolecule Outlook (Revenue, USD Million; 2018 - 2030)

• Genetic Biomarkers

• Epigenetic Biomarkers

• Metabolic Biomarkers

• Proteomic Biomarkers

• Others

Cancer Biomarkers Application Outlook (Revenue, USD Million; 2018 - 2030)

• Drug discovery and Development

• Diagnostics

• Personalized medicine

• Others

Cancer Biomarkers Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Imaging Technology

• OMICS

Cancer Biomarkers Regional Outlook (Revenue, USD Million; 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of Cancer Biomarkers Market

• Abbott

• QIAGEN

• Thermo Fisher Scientific Inc

• Affymetrix Inc

• Illumina, Inc.

• Agilent Technologies

• F. Hoffmann-La Roche AG

• Merck & Co. Inc

• Hologic, Inc

• Sino Biological Inc